1. www.psmarketresearch.com Europe Drug of Abuse Testing Market Size to Reach $3 Billion by 2023

2. Copyright © P&S Market Research Europe Drug of Abuse Testing Market “ “ The European DOA testing market is forecasted to reach $3.0 billion by 2023. Growing alcohol consumption, rising drug trafficking, and increasing government initiatives that aim at increasing interdiction capacities and strengthening law enforcement in the region are some notable factors supporting the demand for DOA testing products and services in the region.European DOA testing market Explore report at: https://www.psmarketresearch.com/market-analysis/europe-doa- testing-markethttps://www.psmarketresearch.com/market-analysis/europe-doa- testing-market

3. Copyright © P&S Market Research Europe Drug of Abuse Testing Market The products category held larger share, of 80.1%, in the European DOA testing market in 2017. This category is predicted to grow at a CAGR of 9.2% during the forecast period, mainly due to the increasing number of drug abuse cases, development of technologically advanced products, and increasing awareness toward DOA testing in the region. The products in the DOA testing market in Europe are further sub-categorized into consumables and equipment. The consumables used for DOA testing are rapid test kits, assay kits and reagents, and others. Of these, rapid test kits held the largest share in the European DOA testing consumables market, and generated more than $400.0 million revenue in 2017. This can be ascribed to the increasing use of these kits at point-of-care settings for the qualitative assessment of drugs and/or their metabolites in human urine for screening, diagnostic purposes, and forensic use. Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=europe- doa-testing-markethttps://www.psmarketresearch.com/send-enquiry?enquiry-url=europe- doa-testing-market

4. Copyright © P&S Market Research Europe Drug of Abuse Testing Market The U.K. DOA testing market is expected to observe the fastest growth, at a CAGR of 11.0% during the forecast period, mainly due to the increasing availability and consumption of illicit drugs in the country. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), in 2017, the prevalence of cannabis use was the highest in the U.K. among all European countries, with drug consumption reported approximately 11.3% in young adults aged 16–34 years. Furthermore, the U.K. government is taking initiatives to address the healthcare challenges in the country by making investments in innovative projects for drug users to overcome drug abuse and addiction. Request for report sample at: https://www.psmarketresearch.com/market-analysis/europe-doa- testing-market/report-samplehttps://www.psmarketresearch.com/market-analysis/europe-doa- testing-market/report-sample

5. Copyright © P&S Market Research Europe Drug of Abuse Testing Market Companies operating in the European DOA testing market are enhancing their product portfolio through new launches. For instance, in October 2018, ACM Global Laboratories announced the release of its therapeutic service offering, Smarter Testing for infectious disease, to address the demand for drug testing in clinical trials. In November 2017, Thermo Fisher Scientific Inc. announced the launch of Thermo Scientific TruNarc handheld narcotics analyzer. This narcotic analyzer can detect Carfentanil, a fentanyl analog, which is 10,000 times more powerful than morphine. Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, bioMérieux S.A., F. Hoffmann-La Roche Ltd., Bio- Rad Laboratories Inc., Abbott Laboratories, Quest Diagnostics Inc., Danaher Corporation, Bioventix Plc, Express Diagnostics Int'l Inc., Psychemedics Corporation, and Lipomed AG are other key players present in the European DOA testing market.

6. Click to edit Master title style Edit Master text styles 2/14/20196 US/Canada Toll-Free: 1-888-778-7886 GET IN TOUCH THANK YOU! For queries, kindly write to: enquiry@psmarketresearch.com www.psmarketresearch.com B-13, Sector-2, Noida, U.P.-201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886